Abstract
To establish a structure and function map of the beta2 integrin subunit, we mapped the epitopes of a panel of beta2 monoclonal antibodies including function-blocking, nonblocking, and activating antibodies using human/mouse beta2 subunit chimeras. Activating antibodies recognize the C-terminal half of the cysteine-rich region, residues 522-612. Antibodies that do not affect ligand binding map to residues 1-98 and residues 344-521. Monoclonal antibodies to epitopes within a predicted I-like domain (residues 104-341) strongly inhibit LFA-1-dependent adhesion. These function-blocking monoclonal antibodies were mapped to specific residues with human --> mouse knock-out or mouse --> human knock-in mutations. Combinatorial epitopes involving residues distant in the sequence provide support for a specific alignment between the beta-subunit and I domains that was used to construct a three-dimensional model. Antigenic residues 133, 332, and 339 are on the first and last predicted alpha-helices of the I-like domain, which are adjacent on its "front." Other antigenic residues in beta2 and in other integrin beta subunits are present on the front. No antigenic residues are present on the "back" of the domain, which is predicted to be in an interface with other domains, such as the alpha subunit beta-propeller domain. Most mutations in the beta2 subunit in leukocyte adhesion deficiency are predicted to be buried in the beta2 subunit I-like domain. Two long insertions are present relative to alpha-subunit I-domains. One is tied down to the back of the I-like domain by a disulfide bond. The other corresponds to the "specificity-determining loop" defined in beta1 and beta3 integrins and contains the antigenic residue Glu(175) in a disulfide-bonded loop located near the "top" of the domain.
Highlights
To establish a structure and function map of the 2 integrin subunit, we mapped the epitopes of a panel of 2 monoclonal antibodies including function-blocking, nonblocking, and activating antibodies using human/mouse 2 subunit chimeras
Antigenic residues 133, 332, and 339 are on the first and last predicted ␣-helices of the I-like domain, which are adjacent on its “front.” Other antigenic residues in 2 and in other integrin  subunits are present on the front
The 12 mAb we mapped to the I-like domain recognized five sets of different epitopes, yet all inhibited binding of LFA-1 to ICAM-1 and ICAM-3 as measured in homotypic adhesion assays
Summary
To establish a structure and function map of the 2 integrin subunit, we mapped the epitopes of a panel of 2 monoclonal antibodies including function-blocking, nonblocking, and activating antibodies using human/mouse 2 subunit chimeras. Monoclonal antibodies to epitopes within a predicted I-like domain (residues 104 –341) strongly inhibit LFA-1-dependent adhesion. These function-blocking monoclonal antibodies were mapped to specific residues with human 3 mouse knockout or mouse 3 human knock-in mutations. The sixth coordination position of the Mg2ϩ is hypothesized to be occupied by an acidic residue in the ligand [8] This residue in ICAM-1 is likely to correspond to Glu-34, which is by far the most critical residue for binding to LFA-1 [12]. MAbs that map to the I domain, but not mAbs that map to surrounding regions in the -propeller domain, block ligand binding by LFA-1 [13] These results show that the I domain in the ␣ subunit of LFA-1 constitutes a ligand binding interface for ICAM-1
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
